Advertisement
Advertisement
OCS
Oculis Holding AG Ordinary shares
31.37
USDSponsored
+0.96
+3.16%
May 13, 16:00 UTC -4
Closed
Pre-Market
31.36
-0.02
-0.05%
OCS Earnings Reports
Positive Surprise Ratio
OCS beat 4 of 13 last estimates.
31%
Next Report
Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
$213.14K
/-$0.45
Implied change from Q1 26 (Revenue/ EPS)
+1.45%
/-8.16%
Implied change from Q2 25 (Revenue/ EPS)
-18.34%
/-8.16%
Oculis Holding AG Ordinary shares earnings per share and revenue
On May 11, 2026, OCS reported earnings of -0.49 USD per share (EPS) for Q1 26, missing the estimate of -0.42 USD, resulting in a -15.83% surprise. Revenue reached 210.09 thousand, compared to an expected 213.14 thousand, with a -1.43% difference. The market reacted with a +5.10% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.45 USD, with revenue projected to reach 213.14 thousand USD, implying an decrease of -8.16% EPS, and increase of 1.45% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Oculis Holding AG Ordinary shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Oculis Holding AG Ordinary shares reported EPS of -$0.49, missing estimates by -15.83%, and revenue of $210.09K, -1.43% below expectations.
How did the market react to Oculis Holding AG Ordinary shares's Q1 2026 earnings?
The stock price moved up 5.1%, changed from $29.58 before the earnings release to $31.09 the day after.
When is Oculis Holding AG Ordinary shares expected to report next?
The next earning report is scheduled for Aug 06, 2026.
What are the forecasts for Oculis Holding AG Ordinary shares's next earnings report?
Based on --
analysts, Oculis Holding AG Ordinary shares is expected to report EPS of -$0.45 and revenue of $213.14K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement